JC09 Rec'd PCT/PTO 0 5 0CT 2005

WR:jam 10/05/05 6395-67856-06 435514 I-023-0

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Marcia L. Kalish et al.

Application No.: To be assigned

Filed: To be assigned

Confirmation No.: To be assigned

For: MULTIPLE ANTIGENIC PEPTIDE

ASSAY FOR DETECTION OF HIV OR

SIV TYPE RETROVIRUSES

Examiner: To be assigned Art Unit: To be assigned

Attorney Reference No.: 6395-67856-06

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV669611391US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

. . .

for Applicant(

Date Mailed October 5, 2005

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this IDS is enclosed.

JC09 Rec'd PCT/PTO 0 5 OCT 2005,

WR:jam 10/05/05 6395-67856-06 435514 I-023-02

. . .

PATENT

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Wayne W. Rupert

Registration No. 34,420

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-67856-06	
Application Number	To be assigned	
Filing Date	To be assigned	
First Named Inventor	Marcia L. Kalish	
Art Unit	To be assigned	
Examiner Name	To be assigned	

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,580,563	03 Dec 1996	Tam
		5,622,933	22 Apr 1997	Sabatier
		6,149,910	21 Nov 2000	DeLeys et al.
		6,150,088	21 Nov 2000	Chan et al.
<u> </u>		6,210,903	03 Apr 2001	DeLeys
		6,372,426	16 Apr 2002	Zens
		6,379,679	30 Apr 2002	Mabrouk et al.
		6,399,067	04 June 2002	Goldstein
		6,509,018	21 Jan 2003	Mauclere et al.
		US 2002/0052469 A1	02 May 2002	Fujii et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
:		Australia	AU 0737857 B2	30 Aug 2001	Institut Pasteur
		WIPO/PCT	WO 93/03766	04 Mar 1993	Repligen Corporaiton and The Rockefeller University
		WIPO/PCT	WO 95/33206	07 Dec 1995	Abbott Laboratories

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

JC09 Rec'd PCT/PTO 0 5 OCT 2005.

	<u></u>			Attorney Docket Nu	ımber	6395-67856-06
			Application Number		To be assigned	
INFOR	MATION	N DISCLOSURE S	STATEMENT	Filing Date First Named Inventor Art Unit		To be assigned
		BY APPLICANT				Marcia L. Kalish
						To be assigned
				Examiner Name		To be assigned
		FO	REIGN PATENT	DOCUMENTS		
Examiner's Initials*	Country Number			Publication Date	A	Name of pplicant or Patentee
		WIPO/PCT	WO 98/26075	18 June 1998		t Pasteur
Examiner's Initials*	Cite No. (optional)		OT	HER DOCUMENTS	3	
		Ayouba et al., "HIV-1 group N among HIV-1 seropositive individuals in Cameroon," <i>AIDS</i> 14(16):2623-2325, November 10, 2000				
				ne heterogeneity in tis		
						1, September 19-22, 1993
Chiodi et al., "Site-Directed ELISA With Synthetic Peptides Representing the H transmembrane Glycoprotein," <i>Journal of Medical Virology</i> 23:1-9, 1987						
		Courgnaud et al., "Partial Molecular Characterization of Two Simian Immunodeficiency				
						Colobus (Piliocolobus
		<i>badius</i>) and SIVol 77(1):744-748, Ja		bus (<i>Procolobus veru</i>	ıs)," Joi	ırnal of Virology
		Courgnaud et al., "Identification of a New Simian Immunodeficiency Virus Lineage with				
	·	a vpu Gene Present among Different Cercopithecus Monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon," Journal of Virology 77(23):12523-12534, December 2003				
* "		Fenouillet et al., "Early and specific diagnosis of seropositivity of HIVs by an anzyme-				
		1990			_	s," Aids 4:1137-1140,
Gnann, Jr. et al., "Fine Mapping of an immunodominant Domain in the Trans Glycoprotein of Human Immunodeficiency Virus," <i>Journal of Virology</i> 61(8) August 1987				rology 61(8):2639-2641,		
		Hahn et al., "AIDS as a Zoonosis: Scientific and Public Health Implications," <i>Science</i> 287:607-614, January 28, 2000				
		Kent et al., "B-cell Epitopes on the Envelope Glycoproteins of SIV and HIV-2," pp. IV-5 to IV-21, December 1996				
						ptides as the antigens to 57:51-54, November 1,
EXAMINE	2		ı	ATF		

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/552182 JC09 Rec'd PCT/PTO 0 5 OCT 2005

			Attorney Docket Number	6395-67856-06
			Application Number	To be assigned
INFORMATION DISCLOSURE STATEMENT		Filing Date	To be assigned	
		SY APPLICANT	First Named Inventor	Marcia L. Kalish
			Art Unit	To be assigned
			Examiner Name	To be assigned
Examiner's Initials*	Cite No. (optional)	OT	HER DOCUMENTS	
		Masciotra et al., "Serological Detect Immunodeficiency Viruses Using Co Laboratory Immunology 7(4):706-70	onsensus env Peptides," Clini	1
		Ndongmo et al., "New multiple antigenic peptide-based enzyme immunoassay for detection of simian immunodeficiency virus infection in nonhuman primates and humans," <i>J. Clin. Microbiol.</i> 42(11):5161-5169, November 2004		
		Peeters et al., "Risk to Human Health from a Plethora of Simian Immunodeficiency Viruses in Primate Bushmeat," CDC 8(5):1-12, May 2002		
	Reeves et al., "Human immunodeficiency virus type 2," <i>Journal of General Virolog</i> 83:1253-1265, June 2002			
		Ribeiro-Rodrigues et al., "Performance characteristics of a rapid new immunochromatographic test for detection of antibodies to human immunodeficiency virus," Clin. Diagn. Lab. Immunol. 10(2):303-307, March 2003		
		Santiago et al., "Amplification of a Complete Simian Immunodeficiency Virus Genome from Fecal RNA of a Wild Chimpanzee," <i>Journal of Virology</i> 77(3):2233-2242, February 2003		
		Shin et al., "Use of Multiple Antigenic Peptides as Coating Antigens in Detection of Antibody," Mol. Cells. 6(2):169-175, 1996		
	Shin et al., "The Use of Multiple Antigenic Peptide (MAP) in the Immunodiagnosis of Human Immunodeficiency Virus Infection," <i>Biochemistry and Molecular Biology International</i> 43(4):713-721, November 1997			
		Simon et al., "Synthetic peptide strat highly divergent primate lentiviruses 1, 2001	s," Aids Res. Hum. Retrovirus	ses, 17(10):937-952, July
		Tam, "Synthetic peptide vaccine des multiple antigenic peptide system," I 1988		
		Zvelebil et al., "Predictions of linear HIV-1, HIV-2 and SIV mac and the c 242(1):9-21, December 1988		
		International Search Report, Internat published October 28, 2004	ional Publication No. WO 20	004/092724 A3,

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.